Featured News

On October 13, 2022 the Celiac Disease Foundation hosted the Ask-the-FDA Educational Webinar with representatives from the U.S. Food and Drug Administration and Coeliac UK.

Please take one minute to email your Members of Congress to make it easier and safer for those with celiac disease to purchase food items by requiring labels to list the presence of barley and rye, in addition to wheat.

Periodically, the FDA hosts workshops to help researchers understand exactly what the FDA will be looking for (aka “endpoints”) when evaluating the efficacy of a proposed drug.

Dr. Don Kasarda was a teacher, a mentor, and a treasured CDF Medical Advisory Board member since the early 1990s. A dedicated scientist for more than 50 years, he was a recognized expert in wheat gluten proteins and celiac disease.

Today, the U.S. Food and Drug Administration issued a final rule for gluten-free labeling compliance requirements for fermented and hydrolyzed foods.

Concern has been expressed in the celiac disease community that the FDA’s temporary food labeling requirements during COVID-19 apply to gluten. The FDA confirmed that the introduction of unlabeled gluten is not allowed in regulated food products.

We are well on the way to assembling a grassroots advocacy team that can help make celiac disease a national priority in communities across the country

Many people who suspect they have celiac disease choose to start a gluten-free diet right away, without a formal diagnosis. Here's why you shouldn't.

ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.

To ensure our community gets the representation it deserves, we are delighted to announce that we have retained Ben Nicholson, a consultant based in Washington, DC, to provide legislative, policy, and advocacy services for the Foundation.